Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response

BACKGROUND: Cancer vaccines are a promising strategy for cancer immunotherapy. Cancer vaccines elicits a specific cytotoxic immune response to tumor antigens. However, the efficacy of traditional peptide-based cancer vaccines is limited due to the inefficient delivery of antigens and adjuvants to de...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lele, Huang, Jiacheng, Chen, Xiaona, Pan, Caixu, He, Yong, Su, Rong, Guo, Danjing, Yin, Shengyong, Wang, Shuai, Zhou, Lin, Chen, Jianxiang, Zheng, Shusen, Qiao, Yiting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404452/
https://www.ncbi.nlm.nih.gov/pubmed/34452929
http://dx.doi.org/10.1136/jitc-2021-003132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404452/
https://www.ncbi.nlm.nih.gov/pubmed/34452929
http://dx.doi.org/10.1136/jitc-2021-003132

Ejemplares similares